[18F]PSMA-1007 PET/CT显示多发性骨髓瘤弥漫性骨髓受累:是否存在诊疗一体化潜力?
一名71岁男性因慢性贫血(血红蛋白7.3 g/dL)就诊,血清前列腺特异性抗原升高(13 ng/mL)提示前列腺癌,但超声引导下经直肠六分区活检未发现前列腺癌证据。为改进重复活检的引导,行[18F]PSMA-1007 PET/CT,显示前列腺左外周带孤立性PSMA高表达病灶,同时意外发现以溶骨性病变为主的弥漫性骨髓受累,骨活检证实为多发性骨髓瘤。本病例既提示PSMA PET/CT的可能陷阱,也提出PSMA配体在多发性骨髓瘤中是否具有诊断和治疗潜力的疑问。
要点
- PSMA PET/CT在评估前列腺癌时可能意外发现多发性骨髓瘤的弥漫性骨髓受累。
- 骨髓瘤的广泛骨病变可与仅轻度升高的前列腺特异性抗原明显不一致。
- PSMA配体在多发性骨髓瘤中的诊断和治疗潜力尚待明确。
核心结论
- 本病例提示PSMA PET/CT可能存在陷阱,并提出PSMA配体在多发性骨髓瘤中是否具有诊断和治疗潜力的问题。
研究设计与样本
- 本文为个案报道,描述一名71岁男性患者的诊治经过。
主要发现
- 患者血红蛋白7.3 g/dL,前列腺特异性抗原13 ng/mL,超声引导下经直肠六分区活检未发现前列腺癌证据。
- [18F]PSMA-1007 PET/CT显示前列腺左外周带孤立性PSMA高表达病灶,并意外发现以溶骨性病变为主的弥漫性骨髓受累。
- 骨髓的广泛肿瘤负荷与仅相对轻度升高的前列腺特异性抗原明显不一致,后续骨活检证实为多发性骨髓瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 71-year-old man presented with chronic anemia (hemoglobin 7.3 g/dL). Further serum analyses showed elevated prostate-specific antigen (13 ng/mL), suggestive of prostate cancer. However, ultrasound-guided transrectal sextant biopsy did not find any evidence of prostate cancer. In order to improve guidance of intended repeated biopsy, [ 18 F]prostate-specific membrane antigen (PSMA) 1007 PET/CT was performed, which showed a solitary lesion with strong PSMA expression in the left peripheral zone in the prostate gland. Surprisingly, also a diffuse bone marrow involvement with predominantly osteolytic lesions was observed. This massive osseous tumor burden was clearly discordant to the only relatively mild elevated prostate-specific antigen. The subsequent bone biopsy revealed multiple myeloma. This case does not only highlight a possible pitfall on PSMA PET/CT, but also raises the question on how far PSMA ligands may offer diagnostic and therapeutic potential in multiple myeloma.
引用
- Michalski K, Jilg CA, Engelhardt M, et al. Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential? Clin Nucl Med. 2022. PMID: 35619194. doi:10.1097/RLU.0000000000004286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。